Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics

From: Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

Characteristic Patients (n = 30)
Age, years 63.0 (40–78)
Male, n (%) 15 (50)
Time since diagnosis, years 5.5 (0.2a–22.2)
Prior treatment for NETs, n (%)  
  Surgery 23 (76.7)
  Any systemic antineoplastic therapy 15 (50.0)
    Chemotherapyb 10 (33.3)
    Interferonb 7 (23.3)
  Somatostatin analoguesc 6 (20.0)
  Radiotherapyb 1 (3.3)
Origin of NETs, n (%)  
  Gastroenteropancreatic NETs  
    Pancreas 8 (26.7)
    Stomach 1 (3.3)
    Small intestine 10 (33.3)
    Large intestine 3 (10.0)
  Bronchopulmonary NETs  
    Bronchus 4 (13.3)
  Unknown 4 (13.3)
Tumour functionality, n (%)  
  Functioning 19 (63.3)
    Carcinoid tumour 18 (60.0)
    Gastrinoma 1 (3.3)
  Non-functioning 11 (36.7)
  Symptomatic 9 (30.0)
Chromogranin A, μg/L 332.5 (44.1–66,056.0)
Urinary 5-HIAA, μmol/d 114.0 (19.9–1684.1)
Ki-67 index  
  Ki-67 ≤2% 13 (43.3)
  Ki-67 >2% 8 (26.7)
  Not evaluated 9 (30.0)
Performance status: ECOG grade, n (%)  
  0 19 (63.3)
  1 9 (30.0)
  2 2 (6.7)
  1. Data are median (range) unless stated otherwise for quantitative parameters.
  2. 5-HIAA, 5-hydroxyindoleacetic acid; ECOG, Eastern Cooperative Oncology Group; NETs, neuroendocrine tumours.
  3. aThe patient diagnosed 0.2 years before the study (and thus apparently non-compliant with inclusion criteria) had had an earlier misdiagnosis (2 years previously) of vertebral haemangioma that should have been NET metastases.
  4. bPatients who received treatment with radiotherapy, chemotherapy or interferon within 4 weeks prior to study inclusion or who were scheduled to receive it during the study were excluded from the study.
  5. cPatients who received treatment with somatostatin analogues within 6 months prior to study inclusion were excluded from the study.